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Quantiﬁcation of lentiviral vector copy numbers in
individual hematopoietic colony-forming cells shows
vector dose-dependent effects on the frequency and
level of transduction
S Charrier1,2,3, M Ferrand1,2,3, M Zerbato1,2,3, G Pre ´cigout1,2,3, A Viornery1,2,3, S Bucher-Laurent1,
S Benkhelifa-Ziyyat1,2,3, OW Merten1, J Perea1,2,3 and A Galy1,2,3
Lentiviral vectors are effective tools for gene transfer and integrate variable numbers of proviral DNA copies in variable
proportions of cells. The levels of transduction of a cellular population may therefore depend upon experimental parameters
affecting the frequency and/or the distribution of vector integration events in this population. Such analysis would require
measuring vector copy numbers (VCN) in individual cells. To evaluate the transduction of hematopoietic progenitor cells at the
single-cell level, we measured VCN in individual colony-forming cell (CFC) units, using an adapted quantitative PCR (Q-PCR)
method. The feasibility, reproducibility and sensitivity of this approach were tested with characterized cell lines carrying known
numbers of vector integration. The method was validated by correlating data in CFC with gene expression or with calculated
values, and was found to slightly underestimate VCN. In spite of this, such Q-PCR on CFC was useful to compare transduction
levels with different infection protocols and different vectors. Increasing the vector concentration and re-iterating the infection
were two different strategies that improved transduction by increasing the frequency of transduced progenitor cells. Repeated
infection also augmented the number of integrated copies and the magnitude of this effect seemed to depend on the vector
preparation. Thus, the distribution of VCN in hematopoietic colonies may depend upon experimental conditions including
features of vectors. This should be carefully evaluated in the context of ex vivo hematopoietic gene therapy studies.
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INTRODUCTION
Genetically corrected hematopoietic stem cells (HSC) can be used as
an alternative to allogenic HSC transplantation for the correction of
several types of inherited diseases.1 Different vectors have been used
for the gene modiﬁcation of HSC, but recombinant HIV-1-derived
(rHIV) lentiviral vectors (LV) appear to be promising for gene-
modiﬁcation of the long-term repopulating HSC population, as
shown in several preclinical models2–4 and in clinical trials in man.5
Thus, novel clinical applications of rHIV vectors are actively deve-
loped, including for instance a treatment of Wiskott–Aldrich syndrome
(WAS). A LVencoding the WAS protein (WASP) is being developed to
treat this life-threatening X-linked primary deﬁciency.6
Depending on the experimental conditions, rHIV vectors can
transduce variable percentages of cells and integrate variable numbers
of copies of proviral DNA into the genome of target cells. Indeed, it
has been shown that human HSC are permissive to the integration of
multiple copies of rHIV. As high as six integrations per cell have been
detected on average in populations of human hematopoietic cells
engrafted in the bone marrow of immuno-incompetent mice.7 The
stable insertion of genes in hematopoietic progenitor cells has a
signiﬁcant impact as these cells will transmit their genomic heritage
to a considerable number of cells given their proliferation and
differentiation potential. The biological potency of the vector is
expected to correlate positively with the frequency of transduced
cells and also with the number of integration per cell unless transgene
silencing is observed, as suggested in some studies.8 At the same time,
genotoxicity related to the number of vector insertions per cell can
result from inappropriate transgene expression in cells9 or from effects
of elements contained in the integrated cassette,10 thus requiring a
strict control of the number of gene insertion per cell. It is therefore
important to determine the distribution of vector copies in the
infected cell population at the single cell level to assess the efﬁcacy
and safety, that is, the therapeutic window of integrative vectors.
Several methods have been used to measure the transduction
of human hematopoietic cells with LV but there are few reports of
validated techniques to determine vector copy distribution in a
population from single-cell measures. In earlier studies, average
number of vector copies have been measured in cell populations
using Southern blot detection of vector sequences, calibrated on
dilutions of genomic DNA and a housekeeping gene .11 More recently,
quantitative PCR (Q-PCR) has been used to provide more precise
measures and the technique can be calibrated on dilutions of a
plasmid bearing both vector and genomic sequences to determine
average vector copy number (VCN) in a human cell population
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www.nature.com/gttransduced with a rHIV LV.12 Such average values does not provide
any indication on the initial frequency of transduced cells in the target
population nor does it estimate the numbers of integrations in
individual transduced cells. Hematopoietic progenitor cells have the
ability to form colonies arising from a single cell when cultured at low
cell density in semi-solid medium. After a culture period of about
2 weeks in methylcellulose, individual colonies can be picked and the
genomic DNA of the cells can be extracted from these colony-forming
cells (CFC) with proteinase K and phenol/chloroform to determine
the presence or absence of vector by PCR and agarose gels, thus,
determining the frequency of transduced hematopoietic progenitor
cells in the initially-infected population of cells.13 Protocols for the
quantiﬁcation of VCN in CFC by Q-PCR have been reported recently
but not validated with experimental data.14 Here, we have developed a
simpliﬁed method relying on a single-step genomic DNA extraction
and a duplex Q-PCR method to quantify VCN in individual CFC.
We have validated this approach experimentally. Transduced and
cloned human cell lines were generated as controls and used to
demonstrate the feasibility, sensitivity and reproducibility of this
protocol. Measures of VCN in CFC have been used to evaluate various
conditions for the transduction of hematopoietic progenitor cells with
LV encoding the green ﬂuorescence protein (GFP) reporter transgene
(GFP-LV) or WASP (WASP-LV). Results show that the frequency of
transduced CFC and the distribution of VCN in these cells could be
augmented by repeated infection. This approach should be useful to
optimize rHIV transduction protocols and to verify vector safety.
RESULTS
Generation of controlled human cell lines to measure rHIV
vector integration
Transduced human cells containing a known amount of rHIV
integration can serve as control materials to analyze VCN in cells. A
panel of such control cells was generated by infecting the human
ﬁbrosarcoma HT1080 cell line with a GFP-LV, then selecting and
characterizing stably-transduced single-cell clones with variable num-
bers of VCN. HT1080 cells were used because of their rapid growth
and few chromosomal changes from the diploid karyotype (http://
www.lgcstandards-atcc.org/ and Ref. 15). Following transduction with
the vector and two rounds of single-cell cloning, a single HT1080 cell
clone HT4-A was ﬁrst selected and analyzed. Vector insertion sites
were determined with the vector integration tag analysis (VITA)
technique described elsewhere16 showing a single vector insertion in
chromosome 19 (Table 1). Subsequently, this clone was re-infected
with the GFP-LVand two daughter clones displaying different levels of
expression of GFP were selected by single-cell cloning. These HT4-A2
and HT4-A6 cells showed, respectively, three and eight vector inser-
tions in various genomic locations, including the initial insertion in
chromosome 19. The number of vector insertion sites in the HT4-A,
HT4A-2 and HT4-A6 was conﬁrmed by Southern-blot analysis using a
single-restriction enzyme (XbaI) to reveal the LV integration banding
pattern. As shown in Figure 1a, we observed one band in clone HT4-
A, three bands in HT4-A2 and eight bands in clone HT4-A6. With the
slight over-exposition of the blot, a very weak band appears at about
8kb in all HT4 clones and corresponds to a nonspeciﬁc hybridation in
the stringency conditions used in the experiment.
In previous studies, we have used a duplex Q-PCR for comparative
ampliﬁcation of vector-speciﬁc sequences (human immunodeﬁciency
virus or woodchuck hepatitis post-transcriptional regulatory element)
versus a human cellular gene (the human albumin gene (ALB)f o r
which two copies are present per cell) to determine the number of
rHIV vector insertions in human cells.12 The reaction is calibrated by a
standard curve made by serial dilutions of a plasmid carrying a single
copy of vector bearing WPRE and of the ALB sequence (see supple-
mentary Table S1). Analysis of the genomic DNA from HT4-A, HT4-
A2 and HT4-A6 cell clones by such Q-PCR protocol determined
1.1±0.2, 2.8±0.7 and 7.1±1.3 VCN in repeated experiments
(Table 1). These results were consistent with the determination of
vector insertions by VITA and by Southern blot in each of the clones.
The numbers of vector copy also correlated strongly with the expres-
sion of the integrated GFP transgene in the different cell clones as
determined by the mean ﬂuorescence intensity of the cells in ﬂow
cytometry (Figure 1b).
Such concurring results from VITA, Southern blot, Q-PCR and ﬂow
cytometry characterize these three cell lines, which can be used for
analytical purposes as a panel of control cells carrying a known range
of rHIV vector integrations.
Validation of the Q-PCR method to determine VCN in
hematopoietic progenitor cells
Hematopoietic progenitor cells are endowed with sufﬁcient prolifera-
tion potential so that single progenitor cells can form visible colonies
when cultured in semi-solid medium in the presence of cytokines.
Table 1 Characterization of vector copies and vector insertion sites in HT1080 clones
Clones VCN by Q-PCR (Taqman) Insertion site analysis by VITA (n¼2)
nV C N A v e ±s.d. (extremes) Nb IS Size(bp)_Chrom(no.)_Position Gene Description function
HT4-A 37 1.1±0.2 (0.74–1.5) 1 107_19_13093976 BTBD14B Transcriptional regulator
285_8_81041615 MRPS28 Mitochondrial ribosomal protein
HT4-A2 16 2.79±0.65 (1.9–3.6) 3 183_14_71097682 SIPA1L1 Signal-induced proliferation-associated protein
107_19_13093976 BTBD14B Transcriptional regulator
164_3_178970571 No gene
136_17_10245972 MYH8 Myosin heavy chain 8, skeletal muscle
114_17_44346886 UBE2Z Ubiquitin-conjugating enzyme E2Z
HT4-A6 17 7.13±1.32 (5.3–8.7) 8 330_17_77173163 NPLOC 4 Nuclear protein localisation 4
63_12_61459846 PPM 1H Protein phosphatase 1H
68_7_19590033 No gene
62_7_101494262 CUX-1 Cut-like homeobox 1a
107_19_13093976 BTBD14B Transcriptional regulator
Abbreviations: Q-PCR, quantitative-PCR; s.d., standard deviation; VCN, vector copy numbers; n, number of Q-PCR experiments.
The bold data represent the identical insertion that is expected to be found in the three different cell lines.
Lentiviral transduction measured by Q-PCR on CFC
SC h a r r i e ret al
480
Gene TherapyThe transduction of hematopoietic progenitor cells can therefore be
assessed at the clonal level by measuring VCN in a single unit of
CFC in which all cells originate from a single progenitor cell.
This prompted us to assess if the duplex Q-PCR technique that we
employed previously could be used to quantify VCN in CFC. One
technical challenge is that CFC contain small numbers of cells
(between 1000–10000 cells) requiring speciﬁc DNA extraction
method, therefore requiring an evaluation of the sensitivity, feasibility
and robustness of the approach.
First, we determined if the sensitivity of our Q-PCR protocol would
be adequate in this desired cell number range. Serial dilutions of the
standard curve plasmid showed the expected ampliﬁcation of HIV
versus ALB or WPRE versus ALB sequences with as little as 102 copies
of plasmid corresponding to 8.26 10 7ng of DNA per reaction
(see supplementary Table S1). The ampliﬁcation of HIV or WPRE
sequences was considered to be equivalent. Considering the size of the
plasmid in relation to the size of the human genome and the amount
of DNA per cell, this level would be compatible with the ampliﬁcation
of the integrated proviral vector DNA in approximately 100 cells. The
sensitivity of the Q-PCR is therefore in principle adequate for the
analysis of CFC.
Second, we determined whether we could amplify small amounts of
cellular genomic DNA material under conditions compatible with the
study of CFC. Extraction of genomic DNA from CFC was performed
by a single-step proteinase K lysis, which is reportedly successful with
small numbers of cells.17 The effects of cell number and of the
extraction conditions were tested. Genomic DNA was obtained from
decreasing numbers of HT4-A, HT4-A2 and HT4-A6 cells after
extraction with proteinase K in the presence or not of methylcellulose.
As shown in Figure 2a, the cycle threshold (CT) for the ALB sequence
increased correspondingly to the reduction in cell sample size. The
lowest amount of genomic DNA that could provide an interpretable
signal with a CTof 31.2±0.5 (n¼94) corresponded to 100 cells, thus
conﬁrming the range of predicted sensitivity of the Q-PCR. The
Figure 1 Characterization of the HT4-A, HT4-A2 and HT4-A6 clones.
(a) Southern Blot on XbaI-digested genomic DNA from the HT1080 clones.
The probes bands are the XbaI fragments released from an internal region to
the vector and the ﬂanking genomic DNA. (b) Correlation between VCN
obtained by Q-PCR and MFI obtained by ﬂow cytometry in the three clones.
Figure 2 Determination of VCN by Q-PCR. (a) The sensitivity of the Q-PCR was evaluated by measuring CT values (average of duplicate measures) for the
ampliﬁcation of the albumin gene sequences in decreasing numbers of control cells. Q-PCR was carried out from 1/6 of the total genomic DNA extracted
from 500–50000 cells. (b) VCN in the HT4-A, HT4-A2 and HT4-A6 clones were measured after proteinase K lysis extractions of separate preparations of
cells ranging from 500–50000 cells per condition. The Q-PCR was performed on 1/6 of the extracted genomic DNA as in Figure 2a. The control indicated
on the right side of the graph corresponds to Q-PCR on genomic DNA obtained from 1 106 cells extracted with a commercial Promega kit. (c) Comparison
of VCN values obtained on the three clones using genomic DNA extracted either by proteinase K lysis from a number of cells inferior to 5 104 or using a
commercial kit and 1 106 cells per extraction. (d) Comparison of VCN values obtained by Q-PCR from the three clones using genomic DNA extracted by
proteinase K lysis in the presence (5ml per condition) or absence of methylcellulose.
Lentiviral transduction measured by Q-PCR on CFC
S Charrier et al
481
Gene Therapydetermination of VCN from variable amounts of genomic DNA
obtained from each of the clones showed similar values over the
range of cell-equivalent tested (Figure 2b). However, lower VCN
values than expected were obtained from the Q-PCR ampliﬁcation of
small amounts of genomic DNA extracted with proteinase K from
HT4-A, HT4-A2 and HT4-A6 cells (Figure 2b). Under these condi-
tions, the copy number was inferior by about 30–40% from the
expected value. With the six cell dilutions shown in Figure 2b, clone
HT4-A gave an average of 0.7±0.1 VCN (range 0.6–0.8), which is
30% less than expected value of 1; HT4-A2 gave an average of 1.7±0.4
VCN (range 1.3–2.5), which is 40% less than expected value of 3; and
HT4-A6 gave an average of 5.7±0.5 VCN (range 5–6.4), which is 30%
less than expected value of 8. To understand the origin of this
suboptimal accuracy, we investigated several parameters. Copy num-
bers measured from genomic DNA obtained from large numbers of
cells with a commercial DNA extraction kit were close to the expected
values (VCN 0.97, 3.12 and 7.1 for each of the three clones) (Figure 2b
controls on the right side of graph), demonstrating the accuracy of the
Q-PCR ampliﬁcation step in itself when it is performed on optimal
material. The quality of the genomic DNA was therefore examined.
The proteinase K extraction method was found to give lower VCN
values than a commercial DNA extraction kit even with large numbers
of cells, although this lower trend was not found to be statistically
signiﬁcant (Figure 2c). The presence or absence of methylcellulose
with the cells did not signiﬁcantly impact the values of VCN in
the clones (Figure 2d). Thus, the genomic DNA extraction step
in itself appears to be a critical parameter for the accuracy of
VCN determination in CFC by Q-PCR. The advantage of the rapid
single-step proteinase K procedure must therefore be mitigated by an
underestimation of VCN values by 30–40%. However, with this
limitation deﬁned, the approach remains useful and provides dose-
dependent results in order to evaluate the distribution of VCN at the
clonal level.
Third, we used this Q-PCR technique to evaluate the transduction of
cord blood CD34+ hematopoietic progenitor cells with various con-
centrations of the GFP-LV by comparing the number of vector copies
in relation to transgene expression in individual CFC. Infected CD34+
cells were seeded in methylcellulose and after 2 weeks, colonies were
scored under epiﬂuorescence microscopy to determine GFPexpression.
Genomic DNA was extracted from each colony with proteinase K to
measure vector copies by duplex Q-PCR. The colonies were scored
positive for vector when they displayed a speciﬁc signal even though
VCN values could be lower than one copy per cell (cut-off value 0.1).
Under these conditions, a positive correlation (r2¼0.92; n¼13) was
found between the frequency of CFC expressing the GFP protein and
scoring positive for vector by Q-PCR (Figure 3). There were only
4±7% of CFC scored positive by microscopy that had no detectable
vector integration by qPCR and inversely, only 6±5% of CFC scored
negative by microscopy that gave a positive signal by qPCR.
It has been proposed that the probability of transduction of single
hematopoietic cells in a preparation can be estimated from the average
mean transduction rate using the Poisson distribution analysis.18
Assuming that each cell has equivalent probability of being transduced
and that the distribution of events is not modiﬁed by cell culture, then
the transduction rate can predict the percentage of cells receiving at
least one copy of vector. The transduction rate can be estimated from
the mean average copy number per cell in a whole population of cells.
In a series of experiments, CD34+ cells were infected with the GFP-LV
at 2 108IG per ml giving mean average VCN of 1.4±0.4 in the whole
population (n¼3 experiments) and in this set of experiments, the
presence of vector was measured by Q-PCR on CFC (Table 2 and
Figure 5a). This showed 70% vector-positive individual CFC (Table 2
and Figure 5a), which is close to the expected transduction efﬁciency
of 65% calculated from the Poisson distribution as per Ref. 18. Similar
ﬁndings were made with another vector. In six independent transduc-
tions of CD34+ cells with a WASP-LV vector, we measured a mean
average value of 0.4±0.1 vector copies per cell in the cultured whole
cell population (data not shown). In one of these six experiments,
the transduction frequency of CFC was found to be 40% by Q-PCR
(Table 2), which is also very close to an expected 35% transduction
frequency on the basis of Poisson distribution.
Altogether, these results experimentally validate the feasibility of
using Q-PCR to quantify the frequency of transduction in single CFC.
Figure 3 Correlation between GFP-positive CFC observed by microscopy and
vector-positive CFC evaluated by Q-PCR (n¼13 experiments).
Table 2 Effects of vector concentration on the transduction of CFC








GFP-LV (ultracentrifuged) n¼3 experiments 2 107 120 48 0.9 (0.1–4.9)
20 107 120 70 1.2 (0.1–12.7)
WASP-LV (ultracentrifuged) n¼2 experiments 5 107 78 27 1.1 (0.2–4.4)
10 107 73 32 0.9 (0.1–7.1)
WASP-LV (chromatography-puriﬁed) n¼2 experiments 5 107 143 40 0.5 (0.1–11.9)
10 107 40 50 0.7 (0.2–4.5)
Abbreviations: CFC, colony-forming cell; GFP-LV, green ﬂuorescence protein-lentiviral vector; VCN, vector copy numbers.
These experiments are also related in Figure 5 (see Figure legend).
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concentration and number of hits on the transduction of
hematopoietic progenitor cells
Various parameters, such as the concentration of vector and the
number of hits of vector, can be adapted to optimize the infection
of hematopoietic progenitor cells with LV. Increasing concentrations
of a GFP-LV augmented the percentage of GFP-expressing cells in the
bulk population of cultured CD34+ cells as expected19 and augmented
the mean average VCN in the population (Figure 4a), thus, resulting
in a good correlation between transgene expression and cell transduc-
tion (Figure 4b). At the individual progenitor cell level, increasing the
concentration of LV increased the frequency of transduced CFC
(Table2 and Figure 5a). In addition, this also modiﬁed the distribution
of VCN in the progenitor cell population as shown by increased
median values or range of VCN when using higher vector concentra-
tions (Table 2). The frequency of CFC containing greater than two
vector copies per cell was also augmented as represented by categories
of frequency according to VCN in Figure 5a. Yet, in the conditions
tested, the majority of transduced CFC only integrated one copy
of vector per cell.
The effects of multiple rounds of infection on CFC transduction
were analyzed. CD34+ cells were infected once for 6h or twice in a
consecutive manner, by adding the same concentration of vector for a
second time. A second hit of infection with the GFP-LV had little
impact on the frequency of vector-positive CFC as seen in Table 3, but
instead, it shifted the median of VCN values from 1.4 to 2.2. This
Figure 5 Effects of experimental conditions on the frequency of transduction and on the distribution of vector copies in the population. CFC with VCN values
comprised between 0 and 0.1 were categorized as 0; those comprised between 0.1 and 1.1 were categorized as 1; those comprised between 1.2 and 2.1
were categorized as 2 and those with VCN superior to 2.1 were categorized as 42. Bars represent average percentage of CFC in each category over the total
number of CFC analyzed. The number of CFC analyzed is indicated between brackets for each graph. (a) Transduction with an ultracentrifuged GFP-LV using
various concentrations of vector. Results represent data pooled from three separate transduction experiments. (b) Transduction with an ultracentrifuged
WASP-LV using several concentrations of vectors and either one or two consecutive infections (hits). Results represent data pooled from two separate
transduction experiments. (c) Transduction with the GFP-LV at concentration of 2 108IGml 1 given once or twice. Results represent data pooled from two
separate transduction experiments. (d) Transduction with two batches of chromatography puriﬁed WASP-LV using two concentrations. Data from one
experiment.
Figure 4 (a) Transduction of CD34+ cells with increasing concentrations of a GFP-LV tested from 0.1 to 10 107IGml 1 in eight independent experiments.
Results show the mean average VCN determined on the cells expanded in liquid culture in the presence of cytokines for 2 weeks after genomic DNA kit
extraction (mean±s.d.). (b) Correlation between average VCN and the frequency of GFP expression measured by FACS in 40 experiments in which various
GFP-LV vector concentrations were tested.
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are found in categories of cells with VCNequal or superior to two. The
range of VCN obtained after infection with the GPF-LV is very broad,
even with one hit. In contrast, performing a second hit with the
WASP-LV, increased the frequency of transduced CFC but did not
modify the median or range of VCN values (Table 3). However, it
increased the percentage of CFC with two copies of vector (Figure 5b)
without signiﬁcant impact on higher categories. Thus, these results
show that different types of LV have the potential to behave differently
according to the experimental conditions. With the WAS-LV tested
here, the transduction efﬁciency could be more effectively augmented
by two consecutive hits of vector rather than doubling the vector
concentration.
Application of the Q-PCR on CFC to evaluate the activity
of a puriﬁed WASP-LV
In the perspective of clinical gene therapy studies for WAS, we have
developed a large-scale puriﬁcation process for the WASP-LV using
chromatography and membrane steps.20 Preparations of chromato-
graphy-puriﬁed WASP-LV were generated during this development
phase and were previously reported.21 Two batches of chromatogra-
phy-purifed WASP-LV were tested here to determine the ability to
transduce individual CFCs in comparison with the same vector
concentrated by ultracentrifugation. Comparable levels of transduc-
tion were found between these two types of preparations as shown in
Table 2. Approximately 40–50% of the CFC were transduced with the
chromatography-puriﬁed vector compared with about 30% with the
ultracentrifuged vector, but the median of VCN were slightly higher in
the latter (0.9–1.1) than the former (0.5–0.7). Approximately 90% of
the CFC that were transduced with the chromatography-puriﬁed
WASP-LV had less than two vector copies per cell as shown in
Figure 5d (with both concentrations tested, 3% of CFC have 42
VCNand 7–8% have two VCN). Thus, contrary to what observed with
the GFP-LV, increasing the concentration of the WASP-LV improved
the transduction frequency, yet, had little effect on VCNaugmentation
per cell. This suggests that a plateau of transduction was probably
reached with the highest value of 108IG per ml of this preparation of
LV. In a non-mutually exclusive manner this also suggests that
different preparations of LV may have different infectivity properties
for hematopoietic progenitor cells.
Transduction of hematopoietic cell subsets
To assess the transduction of the different types of hematopoietic
progenitor cells, we examined the effects of the GFP-LVand WASP-LV
on the VCN values in each type of hematopoietic colony, combining
all experimental conditions tested for each vector. This showed that
the VCN were within a similar range in colony-forming units (CFU)-
granulocyte, monocyte (GM) and CFU-granulocyte, erythrocyte,
monocyte, megakaryocyte (GEMM) colonies and in majority inferior
to four copies per cell as 83% of the CFC were transduced with the
GFP-LV (Figure 6a) and 96% of the CFC were transduced with the
WASP-LV (Figure 6b). However, it is also remarked that both GFPand
WASP LV generate higher VCN values in erythroid colonies (colony-
forming unit, erythroid (CFU-E)/burst-forming unit, erythoid
(BFU-E)) than in myeloid and/or mixed colonies (CFU-GEMM).
The difference between VCN values in erythroid colonies versus other
categories alone or combined, is statistically signiﬁcant (Po0.05,
Student’s t test).
DISCUSSION
We herein describe and validate an analytical method to measure
rHIV VCN in human CFC, providing experimental data on the
transduction of hematopoietic progenitor cells, in particular with a
relevant WASP vector.
The method described in this paper is simple and rapid, comprising
a single-step extraction of genomic DNA followed by a duplex Q-PCR
to amplify the vector and cellular sequences simultaneously. This
simplicity presents an advantage over previously-published protocols
that analyze the presence of gene transfer vectors in hematopoietic
colonies with protocols combining cell lysis, DNA extraction with
phenol chloroform or isopropanol, PCR ampliﬁcation and agarose
gene analysis.4,13 More recent protocols combine these DNA extrac-
tion methods with Q-PCR analysis,14 but to our knowledge, without
being validated experimentally. Thus, we herein show that a simple
protocol can be used and is sufﬁciently sensitive to reliably determine
the frequency of transduced CFC according to expected values.
Following transduction of CD34+ cells with a GFP-LV, there is a
good correlation between the frequency of PCR-positive CFC and the
expression of the transgene. In addition, the transduction frequency of
CFC is coherent with values calculated from the average copy number
in the bulk population of CD34 cells using Poisson’s distribution of









GFP-LV 1 78 56 1.4 (0.1–14.5)
2 79 62 2.2 (0.1–20.9)
WASP-LV 1 151 29 0.9 (0.1–7.1)
2 155 53 1 (0.1–6.5)
Abbreviations: CFC, colony-forming cell; GFP-LV, green ﬂuorescence protein-lentiviral vector;
VCN, vector copy numbers.
These experiments are also related in Figure 5 (see Figure legend). Vectors were tested at the
concentration of 2 108IGml 1 (GFP-LV) or 0.5-1 108IGml 1 (WASP-LV) and data were
pooled from two separate transductions with each vector.
Figure 6 Distribution of the VCN in the different type of the CFC (CFU-GM,
CFU-mix and BFU-E) from CD34+ cells transduced by (a)G F P - L Vo r( b)b y
WASP-LV.
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Gene Therapysingle events.18 The precision of the method is comparable with that of
Q-PCR performed in standard conditions. Indeed, comparable stan-
dard deviations are found on the three control cell lines whether using
genomic DNA extraction kits and large amounts of cell material or in
conditions mimicking those used for CFC (see Figures 2b and c). The
method is therefore simple, sensitive and precise. However, the
simplicity of the method must be mitigated by a suboptimal accuracy.
Testing the three control characterized cell lines in the same conditions
as CFC, we ﬁnd a 30–40% underestimation of VCN values compared
with the expected values. This underestimation is not caused by
insufﬁcient quantities of genomic DNA as the Q-PCR is sensitive
within the range of cells analyzed. The limitation is probably caused by
insufﬁcient quality of the genomic DNA, which prevents the optimal
ampliﬁcation of vector-speciﬁc sequences, but the presence of methyl-
cellulose can be excluded as a factor. In spite of this suboptimal
accuracy, VCN results obtained with this simple method provide
coherent results. Indeed, the VCN obtained on the three control cell
lines reﬂect the expected range of rHIV copies inserted in these cells.
The distribution of VCN in individual CFC is consistent with expected
values from an idealized Poisson’s distribution.18 Theoretical calcula-
tions predict that when a mean vector copy number is inferior to two
in a cell population, then among transduced cells the majority of
individual cells should contain one copy of vector. This distribution
was obtained with the GFP-LV or with the WASP-LV and indeed we
measured that the majority (about 60 %) of the CFC contained one
copy. Also, with mean transduction rates inferior to one, an idealized
distribution would predict that less than 10% of individual cells
should contain more than two copies per cell and this is also what
we measured in experiments using the chromatography-puriﬁed
WASP-LV. Thus, in spite of a slight underestimation of the VCN
values in CFC, the distribution of cells according to VCN categories
appears to be consistent with expected data from theoretical calcula-
tions. To take into account this possible underestimation, one could
apply a corrective factor on the basis of the 30–40% underestimation
that was observed with the three control cell lines using this technique.
Altogether, our data show that at this point, the Q-PCR method is
sufﬁciently sensitive, precise and acceptably accurate to provide a
meaningful measure of the frequency of vector-positive CFC and
the distribution of vector copies at the clonal level within a population
of hematopoietic progenitor cells.
Further effort outside the scope of this article are needed to improve
the accuracy of this technique by optimizing the DNA extraction step
or the performance of ampliﬁcation of rHIV sequences in proteinase
K-extracted DNA. In addition, this simple technique could be adapted
to high-throughput analysis to obtain data on large numbers of
clones. Although the use of CFC is a very practical manner to obtain
clones of hematopoietic cells, it is strongly biased for cells of the
myelo-erythroid lineage. Further development could be envisioned
with the analysis of single cell sorted cultures, which could enable the
evaluation of transduction at the single cell level in various hemato-
poietic cell lineages.
Measuring the number of vector copies in individual target cells is
important to assess the therapeutic window of integrative vectors.
Their biological potency but also their inherent risk of genotoxicity is
related to the number of vector copies integrated per cell. Determining
the VCN in hematopoietic progenitor cells in relation to gene
expression in these cells or their progeny, could be used to gauge
the biological activity of the integrated cassette and may reveal
potential occurrence of gene silencing as suggested by some studies.8
In order to evaluate the genotoxic potential of vectors, the Q-PCR on
CFC method could be used in combination with an analysis of vector
insertion sites. Three characterized human cell lines, which we have
been derived from HT1080 cells, could be relevant controls for both
types of analytical measures. These cells contain known numbers of
rHIV integration, which are in the range of events expected to occur
following transduction of HSC. In addition, these cells contain known
sites of rHIV integration, which could also serve as references for
quality control and validation of protocols aiming to identify vector
insertion sites.
Following transduction of CD34+ cells with the two different LVs
tested in our study, revealed a slight bias in the distribution of VCN in
the different types of progenitor cells. BFU-E seemed to integrate more
copies than CFU-GM or CFU-GEMM. As erythroid cells arise from
primitive cells such as CFU-GEMM, this would indicate that the
experimental conditions favoured the preferential transduction of
erythroid-restricted progenitor cells. This is not unexpected as
the transduction medium contained stem cell factor (SCF) and
thrombopoietin (TPO), which may provide a strong erythroid pro-
genitor cell stimulus. Alternatively, we cannot exclude that the
measure of VCN is not as accurate or precise in erythroid colonies
as in other cells. Erythroid-restricted colonies are composed of cells
that start to compact their chromatin in the course of their develop-
ment. Further studies are needed to address this point more thor-
oughly, in particular, in the context of gene therapy studies targeting
erythroid progenitor cells.
There is a strong interest in optimizing the conditions for ex vivo
hematopoietic gene transfer in the perspective of experimental
or clinical applications. Several previous studies have optimized
parameters such as cell concentration, cytokines, medium, timing,
concentration of vector, multiplicity of infection or number of
transduction hits with rHIV vectors. In many cases, such studies
were performed with GFP-encoding LV, relying on transgene expres-
sion levels8,19,22 but providing little to no information on the amount
of vector integrated in target cells or the frequency of the targeted
population. In this paper, we show that the Q-PCR analysis of CFC is
applicable to evaluate the infectivity of CD34+ cells with LV in a
transgene-independent manner. Increasing the concentration of infec-
tious vector or repeating the infection were two different but effective
ways to augment the level of transduction as measured by the
percentage of vector-positive cells and by the distribution of VCN
within transduced cells. In some experiments, repeating the infection
seemed more effective than increasing the vector concentration to
augment the percentage of vector-positive colonies as seen in
Figure 5b. This indicates that clonogenic cells could become more
permissive to rHIV transduction during the ex vivo culture. Further
optimization could be undertaken to increase this effect and improve
the levels of transduction. On the other hand, these results reveal that
two consecutive hits can augment the frequency of progenitor cells
with more than two copies per cell. Therefore a repeat transduction
strategy may become toxic to a fraction of the cells and this should be
carefully tested. The effect of repeated hits on high VCN was clearly seen
with the ultracentrifuged vectors but not with the chromatography-
puriﬁed batches. This information cannot be obtained from gene
expression analyses based on average numbers. To our knowledge, this
is the ﬁrst time that transduction efﬁciency is documented from
quantitative measures of VCN at the single-cell level. Thus, our results
strongly suggest that different preparations could behave differently in
pharmacological terms, for infection of hematopoietic progenitor
cells resulting in variable levels of vector copies per cell. The process
of transduction is complex, but the mechanisms behind the observed
differences in VCN may involve viral binding or entry as well as
proviral integration capacity.
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developed a large-scale puriﬁcation process for rHIV LV as described
in Ref. 21, and more extensively in Ref. 20. The chromatography-
puriﬁed WASP-LV has showed an acceptable safety proﬁle in pre-
clinical tests, notably with respect to hematopoietic progenitor cell
survival and differentiation, as conﬁrmed here. The CFC transduction
levels obtained with this batch of vector were similar to those obtained
with the same WASP-LV puriﬁed by ultracentrifugation. Transduction
is effective (about 40–50% of the CFC can be transduced), whereas
providing only a low number of copies (60–85% of CFC contain 1
copy per cell and 490% of the CFC contain equal or less than two
copies per cell), even after repeat infection. If we take into account that
there is possibly an underestimation factor for VCN in CFC and apply
a 30–40% correction, then 490% of the cells would have no more
than three copies per cell. Thus, although a probability exists that
some cells will integrate high VCN, our data suggest that the
chromatography-puriﬁed WASP-LV provides a relatively safe level of
transduction of hematopoietic cells.
In conclusion, the analysis of vector copy number in individual
CFC with Q-PCR determines the frequency and the distribution of
vector copies in the population of hematopoietic progenitor cells that
were initially targeted by the vector. It is clear that these values are
inﬂuenced by the experimental transduction conditions and by the
type of vector tested. Such data are important to optimize preclinical
and clinical transduction protocols with LVs for ex vivo hematopoietic
gene therapy applications.
MATERIALS AND METHODS
Generation and titration of lentiviruses
The PGK-GFP/VSVg rHIV vector (GFP-LV) or w1.6hWASP/VSVg rHIV vector
(WASP-LV) were produced by transient quadri-transfection of 293T cells and
were puriﬁed by ultracentrifugation as previously reported.12 In some experiments
a WASP-encoding LV produced similarly by transient transfection was concen-
trated and puriﬁed through a series of chromatography and membrane steps as
reported.20 Vectors were titered as infectious genomes (IG) per ml on HCT116
cells using duplex Q-PCR as previously described12 and were also titered for p24
levels using an ELISA (Perkin Elmer, Waltham, MA, USA). In some experiments,
vectors encoding the GFP were titered by ﬂow cytometry instead, and results were
multiplied by a factor 2 to match with IG values, as determined by repeated
comparisons between the two titration methods (data not shown). Vector batches
used in the study are listed in supplementary Table S2.
Clones derived from HT1080 cells
The ﬁbrosarcoma HT1080 cells originated from ATCC (CCL-121, American
Type Culture Collection, Manassas, VA, USA) were grown in DMEM supple-
mented with glutamine and antibiotics, and containing 10% fetal calf serum.
HT1080 cells were transduced with a rHIV encoding the GFP under control
of the human phosphor-glycerate kinase promoter kindly provided by
Dr L Naldini (Tiget, Milan, Italy). Expression of GFP was measured by ﬂow
cytometry. Using the same culture medium, the cells were ﬁrst cloned by
ﬂuorescence-activated cell sorting and then a second cloning was performed by
limit dilution culture. One clone (HT4-A) containing one copy was identiﬁed
and further transduced with the same vector to generate subclones. Such
re-infected HT4-A cells were then cloned by limit dilution and wells were
screened by ﬂuorescent microscopy and ﬂow cytometry to identify cells
presenting different mean ﬂuorescence intensity for GFP expression. Two
daughter clones (HTA-A2 and HT4-A6) expressing different levels of ﬂuores-
cence were selected and characterized by Q-PCR, Southern blot and sequencing.
Southern Blot
The number of rHIV insertions in HT4, HT4-A2 and HT4-A6 cells was
determined by Southern blot using genomic DNA extracted by chloroform/
phenol extraction with AutoGen extractor, NA2000 (Geneworx, Ble ´nod le `s
Pont a ` Mousson, France) after proteinase K (Invitrogen, Cergy Pontoise,
France) lysis. A measure of 40mg of genomic DNA of each cell sample was
digested with 70 units of XbaI (Gibco BRL/Invitrogen, Cergy Pontoise, France)
at 371C over night and the digested DNA samples were subjected to an 0.8%
agarose gel electrophoresis. The DNA fragments in the gel were transferred onto
a Nylon membrane (Amersham, Piscataway, NJ, USA). The membrane was
hybridized with 50% deionized formamide over night at 421C with a 2185bp
fragment of the integrative lentiviral DNA obtained by AﬂII-BamHI digestion
of the plasmid pCCLsincppthPGK-GFP-WPRE and labeled with [a-32P]dATP
using the Prime-it Random Primer Labeling kit (Stratagene, Lyon, France). The
ﬁnal wash was preformed with 0.1  SSC-1% SDS at 681C for 1h. After 10 days
of exposure on a phosphor screen (Molecular Dynamics PhosphorImager
System; GE Healthcare Bio-Sciences, Piscataway, NJ, USA), radioactive bands
were revealed by the Storm system (GE-Healthcare Bio-Sciences).
Analysis of vector genomic insertion sites
rHIV insertion sites were determined following NlaIII digestion of the genomic
DNA of HT4-A, HT4-A2 and HT4-A6 cell clones as described previously.16
Sequencing reactions were performed using Big Dye terminator sequencing
chemistry (Applied Biosystems, Carlsbad, CA, USA) from the M13 forward or
M13 reverse primers and run on a 377-XL Applied Biosystems automated
sequencer. Junctions obtained were matched on the human genome using the
BLAT program (UCSC human Genome Working draft (March 2006 (NCBI36/
hg18). The description of the human transcripts was obtained from ftp://
hgdownload.cse.ucsc.edu.
Human CD34+ cells source, transduction and culture
Umbilical cord blood progenitor CD34+ cells were obtained by immunomag-
netic selection (Miltenyi Biotec, Paris, France) from mononuclear cell fractions
of cord blood samples obtained from uncomplicated births at Hopital Louise
Michel, Evry, France, in compliance with French national bioethics law. Cells
were ﬁrst pre-activated by culturing overnight 5 104 cells in 0.2ml of X-vivo20
medium (Lonza, Levallois Perret, France) supplemented with 50Uml 1 peni-
cillin, 50mgml  1 streptomycin and 2mML -glutamine (Gibco BRL/Invitrogen),
SCF (25ngml 1), Flt-3 ligand (50ngml 1), TPO (25ngml 1), IL-3
(10ngml 1) (R&D Systems, Lille, France). Pre-activated cells were then infected
with LV using different concentration of vectors ranging from 2 107IG per ml
to 2 108IG per ml for 6h in the presence of polybrene (6mgml  1). When cells
were re-infected, the second hit of vector was added overnight. At the end of the
transduction step, cells were washed and either plated in semi-solid medium for
CFC assays or cultured in the presence of cytokines for in vitro expansion. For in
vitro expansion, the transduced CD34+ cells were seeded at 5 104 cells per ml
in 24-well ﬂat-bottom plates in X-vivo20 medium supplemented with 10% fetal
calf serum (Gibco), penicillin/streptomycin, L-glutamine and the same recom-
binant cytokines as used for transduction. Fresh medium was added every 3
days. Cultures were incubated at 371C5 %C O 2 for 14 days.
CFC assays
CFC assays were performed in duplicate by plating 1000 transduced or untrans-
duced cells per ml of Methocult (H4434), a complete methylcellulose medium
supplemented with human cytokines (Stem Cell Technologies, Vancouver, CA,
USA) according to the manufacturer’s instructions. After 2 weeks of culture, 5%
CO2,3 7 1Ci nh u m i da t m o s p h e r e ,C F U - E /BFU-E, CFU-GM and CFU-GEMM
were counted by inverse microscopy using standard visual criteria.
Q-PCR and analysis of CFC
Well-isolated colonies were aspirated carefully with a pipette tip under the
miscroscope and the cells were suspended into 100ml of phosphate-buffered
saline in a 96-well U-bottom plates. The plates were centrifuged at 1500r.p.m.
for 10min. Green ﬂuorescent (GFP+) colonies were identiﬁed by ﬂuorescence
microscopy. Medium was aspirated and the cells pelleted from each CFC unit
were suspended in 10ml of phosphate-buffered saline. Genomic DNA was
extracted from these pellets using proteinase K lysis consisting in adding 20ml
of lysis buffer (0.3mM Tris HCl, pH 7.5; 0.6mM CaCl2; 1.5 % Glycerol; 0.675%
Tween-20; and 0.3mgml 1 Proteinase K) to each well and incubating the plate
at 651C for 30min, 901C for 10min and at 41C to end the reaction for a
minimum of 10min. After lysis, 30ml of water was added to each well to obtain
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Q-PCR was always carried out from 10ml of this genomic DNA preparation
(that is, amplifying 1/6 of the extracted material), and in duplicate.
The Q-PCR consisted of a duplex detection of WPRE or HIV sequences
normalized to ALB, as described for titrations. The probes were conjugated to
FAM for HIV or WPRE sequences and to VIC for Albumin. Ampliﬁcation
reactions (25ml) contained 10mlo fg e n o m i cD N Aa n d1 5ml of TaqMan buffer
(Absolute Q-PCR Rox Mix, ABgene AB-1139/B), 0.1mM primers (forward and
reverse), 0.1mM TaqMan probe and consisted of 40 cycles at 951C (15s) then
601C (1min) on an ABI PRISM 7700 sequence detector (Applied Biosystems).
Standard ampliﬁcation curves were obtained by serial dilutions of the
pRRLcpptPGKGFP-WPRE-Alb plasmid containing the appropriate sequences
in cis from the vectors and ALB gene. All PCR measures were performed at least
in duplicate. All Q-PCR experiments on CFC include samples from untrans-
duced CFC as negative controls.
Data were edited using the Primer Express software (Applied Biosystems).
Data were interpreted in the linear portion of the standard curve. Linear
regression coefﬁcient of the standard curve should be 40.99. In this portion of
the curve the ratio between HIV/ALB of the plasmid standard is equivalent to
1±0.2 (n¼28). The detection’s threshold is determined with this standard.
When the CTof Albumin is superior to 32 cycles, the ratio HIV/ALB is different
from the value of 1±0.2 deﬁned in the linear portion of the curve. The
duplicate CTshould vary by less than 0.5 CT. The ALB and HIVor WPRE CT
of H2O should locate between 35 and 40. HIV CTof untransduced cells should
be like H2O. ALB CTof untransduced cells and transduced samples should be
around 23–28. The amount of WPRE/ALB or HIV/ALB is equimolar to the
amount of pRRLcpptPGKGFP-WPRE-Alb plasmid. However, because in
diploid cells, there are two molecules of ALB per cell, the number of integrated
VCN per cell is determined by multiplying the ratio WPRE/ALB or HIV/ALB
by two. Results of VCN inferior to 0.1 copy per cell were considered to be
negative.
Preparation of genomic DNA from cells other than CFC for Q-PCR
Genomic DNA from cell lines or from bulk CD34+ were extracted with the
‘Wizard genomic DNA puriﬁcation kit’ (Promega Corporation, Madison, WI,
USA) or with a single-step proteinase K lysis as described above.
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